Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions

Charles V. Pollack(Hospital of the University of Pennsylvania), Jeffrey I. Weitz(McMaster University Medical Centre), J. H Levy, Menno V. Huisman(Leiden University Medical Center), Elaine Hylek, Thorsten Steiner(Heidelberg University), Peter Verhamme(KU Leuven), Robert Dubiel(Boehringer Ingelheim (Germany)), Pieter W. Kamphuisen(University Medical Center Groningen), B Wang(Boehringer Ingelheim (United States)), John W. Eikelboom(Population Health Research Institute), Richard A. Bernstein(Northwestern University), Paul Reilly(Boehringer Ingelheim (United States)), CW Kam(Boehringer Ingelheim (Germany)), J. Kreuzer(Boehringer Ingelheim (United States)), Frank W. Sellke(Brown University)

Journal of Thrombosis and Haemostasis

January 1, 2015

Cited by 2

|New England Journal of Medicine|2009|11.2k

|New England Journal of Medicine|2013|5.2k

|Journal of the American College of Cardiology|2020|2.9k

|New England Journal of Medicine|2017|2.4k

|New England Journal of Medicine|2014|2.2k

Related Papers